BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15195528)

  • 1. [Pharmacological modulation of portal hypertension syndrome: current status and future prospects].
    González García M; Albillos Martínez A
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():1-7. PubMed ID: 15195528
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vasodilator agents in portal hypertension].
    Combis JM; Vinel JP
    Gastroenterol Clin Biol; 1991; 15(12):881-7. PubMed ID: 1686004
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Bosch J
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S131-7. PubMed ID: 15758648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Liver cirrhosis and the renin-angiotensin-aldosterone system].
    Lozano de León F; Leal M; Lissen E
    Rev Esp Enferm Apar Dig; 1986 Nov; 70(5):465-8. PubMed ID: 3797771
    [No Abstract]   [Full Text] [Related]  

  • 5. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological treatment of the portal hypertension].
    Castañeda Romero B
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():64-5. PubMed ID: 17471863
    [No Abstract]   [Full Text] [Related]  

  • 7. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation multifunctional angiotensin receptor blockers.
    Kurtz TW; Klein U
    Hypertens Res; 2009 Oct; 32(10):826-34. PubMed ID: 19713966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers: current status and future prospects.
    Kumar S; Ram CV
    Indian Heart J; 2007; 59(6):443-53. PubMed ID: 19151457
    [No Abstract]   [Full Text] [Related]  

  • 10. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the renin-angiotensin system in liver fibrosis.
    Sancho-Bru P; Ginès P
    Hepatol Int; 2016 Sep; 10(5):730-2. PubMed ID: 27246697
    [No Abstract]   [Full Text] [Related]  

  • 12. [The current status and prospects of surgical management for cirrhotic portal hypertension].
    Li HW; Zhou GW
    Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(22):1681-2. PubMed ID: 19094721
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemodynamics in the isolated cirrhotic liver.
    Zipprich A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients].
    Zhang XX; Guo JS
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):923-928. PubMed ID: 31941254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of extrahepatic vasodilation in portal hypertension.
    Hennenberg M; Trebicka J; Sauerbruch T; Heller J
    Gut; 2008 Sep; 57(9):1300-14. PubMed ID: 18445644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renin angiotensin system and liver fibrosis or cirrhosis].
    Shen FJ; Yin CH; Wang BE
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jul; 11(7):447-8. PubMed ID: 12890362
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemodynamic disorders due to liver cirrhosis].
    Garbuzenko DV
    Klin Med (Mosk); 1996; 74(2):5-7. PubMed ID: 8772089
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy.
    Wagatsuma Y; Naritaka Y; Shimakawa T; Kanako H; Keiichiro I; Shunichi S; Konno S; Katsube T; Ogawa K
    Hepatogastroenterology; 2006; 53(68):171-4. PubMed ID: 16608017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of lisinopril and nebivolol therapy of portal hypertension and kidney dysfunction in patients with liver cirrhosis].
    Fedulenkova LV; Drozdov VN; Mikheeva OM; Petrakov AV
    Eksp Klin Gastroenterol; 2008; (5):37-41. PubMed ID: 19145915
    [No Abstract]   [Full Text] [Related]  

  • 20. Does losartan work after all?
    Blendis LM; Wong F
    Am J Gastroenterol; 2003 Jun; 98(6):1222-4. PubMed ID: 12818261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.